These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 35790023)
1. Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'. Byrne CD Diabet Med; 2022 Oct; 39(10):e14912. PubMed ID: 35790023 [TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship. Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804 [TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease - A multisystem disease? Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470 [TBL] [Abstract][Full Text] [Related]
4. Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis. Scorletti E; Byrne CD Dig Dis; 2016; 34 Suppl 1():11-8. PubMed ID: 27548822 [TBL] [Abstract][Full Text] [Related]
5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499 [TBL] [Abstract][Full Text] [Related]
6. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients. Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414 [TBL] [Abstract][Full Text] [Related]
7. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554 [TBL] [Abstract][Full Text] [Related]
8. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease. Budd J; Cusi K Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726 [TBL] [Abstract][Full Text] [Related]
9. Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. Seo DH; Suh YJ; Cho Y; Ahn SH; Seo S; Hong S; Lee YH; Choi YJ; Lee E; Kim SH Diabetes Metab J; 2022 Jul; 46(4):630-639. PubMed ID: 35081304 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Rhee EJ Endocrinol Metab (Seoul); 2019 Sep; 34(3):226-233. PubMed ID: 31565874 [TBL] [Abstract][Full Text] [Related]
11. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Ranjbar G; Mikhailidis DP; Sahebkar A Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448 [TBL] [Abstract][Full Text] [Related]
12. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. En Li Cho E; Ang CZ; Quek J; Fu CE; Lim LKE; Heng ZEQ; Tan DJH; Lim WH; Yong JN; Zeng R; Chee D; Nah B; Lesmana CRA; Bwa AH; Win KM; Faulkner C; Aboona MB; Lim MC; Syn N; Kulkarni AV; Suzuki H; Takahashi H; Tamaki N; Wijarnpreecha K; Huang DQ; Muthiah M; Ng CH; Loomba R Gut; 2023 Nov; 72(11):2138-2148. PubMed ID: 37491159 [TBL] [Abstract][Full Text] [Related]
15. FSTL3 partially mediates the association of increased nonalcoholic fatty liver disease fibrosis risk with acute myocardial infarction in patients with type 2 diabetes mellitus. Duan W; Shi R; Yang F; Zhou Z; Wang L; Huang Z; Zang S Cardiovasc Diabetol; 2023 Oct; 22(1):297. PubMed ID: 37904173 [TBL] [Abstract][Full Text] [Related]
16. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Arrese M; Barrera F; Triantafilo N; Arab JP Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):849-866. PubMed ID: 31353974 [No Abstract] [Full Text] [Related]
17. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031 [TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease: a diabetologist's perspective. Pappachan JM; Antonio FA; Edavalath M; Mukherjee A Endocrine; 2014 Apr; 45(3):344-53. PubMed ID: 24287794 [TBL] [Abstract][Full Text] [Related]
19. How to Identify Advanced Nonalcoholic Fatty Liver Disease in the Primary Care Setting. Golabi P; Shah D; Younossi ZM Semin Liver Dis; 2023 May; 43(2):142-148. PubMed ID: 37414024 [TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]